Mabxience Expands Biosimilar Capacity
Investment In Plant In León, Spain, Also Bolsters CDMO Business
Mabxience has announced plans to bolster its biosimilar manufacturing capacity as well as giving a boost to its CDMO business by expanding its facility in León, Spain.
You may also be interested in...
Jordan-based MS Pharma has struck a deal with Insud Pharma subsidiary Mabxience to commercialize its bevacizumab biosimilar in the Middle East and North Africa region. The move comes after Mabxience partnered with Zentiva to commercialize bevacizumab in 21 European countries. Meanwhile, MS Pharma has also partnered with Alvion Pharma for rosuvastatin/ezetimibe in the MENA region.
In this exclusive video roundtable discussion, leaders from across the off-patent industry talk about the COVID-19 pandemic and the industry’s response, as well as highlighting key regulatory, policy and strategic developments that may have flown under the radar in the past year.
Henlius has struck a deal with Mabxience to market its HLX02 trastuzumab biosimilar in Argentina, Uruguay and Paraguay.